mounjaro tirzepatide prescribing information fda label 2025 pdf https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a expansion for Zepbound Tirzepatide Dosage Guide and Chart

Tirzepatide (Mounjaro, Zepbound) represents a breakthrough in type 2 diabetes and weight management as the first dual GIP/GLP-1 receptor agonist approved by the FDA

Monitor your progress: A doctor can track how your body is responding and make adjustments as needed

This powerful mechanism drives weight loss but can also reduce bowel movement frequency, causing constipation in roughly one in five patients during the first weeks of therapy

GLP-1 Analogues Industry Developments March 2026: Dr

A spokesperson said: As with other misuse, such as review fabrication, bad actors are continuously evolving their tactics in an attempt to circumvent our detection

Both medications are generally safe when prescribed appropriately, but Ozempic's side effects tend to improve with continued use while Jardiance's infection risk persists